It appears the US FDA may be able to influence generic drug sponsors' development priorities with its research projects, or at least pique their interest.
Data suggests that pre-ANDA meeting requests sometimes correlate with the number of internal and external research projects in the category, particularly when it comes to complex generics. Agency studies may...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?